Literature DB >> 31515353

Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis.

Jingshi Wang1, Yini Wang1, Lin Wu1, Xinkai Wang1, Zhili Jin1, Zhuo Gao1, Zhao Wang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31515353      PMCID： PMC7193462          DOI： 10.3324/haematol.2019.222471

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Monocytosis in polycythemia vera: Clinical and molecular correlates.

Authors:  Daniela Barraco; Sonia Cerquozzi; Naseema Gangat; Mrinal M Patnaik; Terra Lasho; Christy Finke; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-05-26       Impact factor: 10.047

2.  MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Authors:  Paola Guglielmelli; Terra L Lasho; Giada Rotunno; Mythri Mudireddy; Carmela Mannarelli; Maura Nicolosi; Annalisa Pacilli; Animesh Pardanani; Elisa Rumi; Vittorio Rosti; Curtis A Hanson; Francesco Mannelli; Rhett P Ketterling; Naseema Gangat; Alessandro Rambaldi; Francesco Passamonti; Giovanni Barosi; Tiziano Barbui; Mario Cazzola; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2017-12-09       Impact factor: 44.544

3.  Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease.

Authors:  Leonardo Boiocchi; Rosanny Espinal-Witter; Julia Turbiner Geyer; Julia Steinhilber; Irina Bonzheim; Daniel M Knowles; Falko Fend; Attilio Orazi
Journal:  Mod Pathol       Date:  2012-09-28       Impact factor: 7.842

4.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

5.  Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.

Authors:  Leonardo Boiocchi; Umberto Gianelli; Alessandra Iurlo; Falko Fend; Irina Bonzheim; Daniele Cattaneo; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

Review 6.  Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.

Authors:  Alessandra Iurlo; Daniele Cattaneo; Umberto Gianelli
Journal:  Int J Mol Sci       Date:  2019-04-13       Impact factor: 5.923

7.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Authors:  A Tefferi; E Rumi; G Finazzi; H Gisslinger; A M Vannucchi; F Rodeghiero; M L Randi; R Vaidya; M Cazzola; A Rambaldi; B Gisslinger; L Pieri; M Ruggeri; I Bertozzi; N H Sulai; I Casetti; A Carobbio; G Jeryczynski; D R Larson; L Müllauer; A Pardanani; J Thiele; F Passamonti; T Barbui
Journal:  Leukemia       Date:  2013-06-06       Impact factor: 11.528

8.  Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Authors:  Ayalew Tefferi; Mythri Mudireddy; Francesco Mannelli; Kebede H Begna; Mrinal M Patnaik; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Meera Yogarajah; Valerio De Stefano; Francesco Passamonti; Vittorio Rosti; Maria Chiara Finazzi; Alessandro Rambaldi; Alberto Bosi; Paola Guglielmelli; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

9.  Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis.

Authors:  Mythri Mudireddy; Naseema Gangat; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-06-11       Impact factor: 11.037

10.  Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

Authors:  Rangit R Vallapureddy; Mythri Mudireddy; Domenico Penna; Terra L Lasho; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Kebede H Begna; Naseema Gangat; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2019-01-25       Impact factor: 11.037
View more
  21 in total

1.  Possible roads to improve hemophagocytic lymphohistiocytosis outcome.

Authors:  Pietro Merli; Michael B Jordan; Franco Locatelli
Journal:  Blood Adv       Date:  2020-12-22

2.  Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.

Authors:  Yubo Pi; Jingshi Wang; Hui Zhou; Xiujin Ye; Xiuhua Sun; Ligen Liu; Xueyi Pan; Zhao Wang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-19       Impact factor: 4.322

3.  Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis.

Authors:  Yue Song; Jingshi Wang; Yini Wang; Lin Wu; Zhao Wang
Journal:  Cancer Biol Ther       Date:  2021-11-01       Impact factor: 4.742

4.  Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.

Authors:  Fu Ming Zi; Long Long Ye; Ji Fu Zheng; Jing Cheng; Qing Ming Wang
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

5.  Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective.

Authors:  Michael P Triebwasser; David M Barrett; Hamid Bassiri; Nancy Bunin; Caitlin Elgarten; Jason Freedman; Abdallah S Geera; Dimitri Monos; Michele P Lambert; Timothy Olson; Alix E Seif; Michele Paessler; Whitney Petrosa; Anne F Reilly; Neil Romberg; Kathleen E Sullivan; Ghazal Z Quinn; Edward Behrens; David T Teachey
Journal:  Pediatr Blood Cancer       Date:  2021-03-22       Impact factor: 3.838

6.  COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.

Authors:  Cirino Botta; Alessia Indrieri; Eugenio Garofalo; Flavia Biamonte; Andrea Bruni; Pino Pasqua; Francesco Cesario; Francesco Saverio Costanzo; Federico Longhini; Francesco Mendicino
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

Review 7.  Primary Immune Regulatory Disorders and Targeted Therapies

Authors:  Burcu Kolukısa; Safa Barış
Journal:  Turk J Haematol       Date:  2021-01-14       Impact factor: 1.831

Review 8.  Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL).

Authors:  Pietro Merli; Mattia Algeri; Stefania Gaspari; Franco Locatelli
Journal:  Front Immunol       Date:  2020-12-02       Impact factor: 7.561

9.  A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.

Authors:  Qing Zhang; Ang Wei; Hong-Hao Ma; Li Zhang; Hong-Yun Lian; Dong Wang; Yun-Ze Zhao; Lei Cui; Wei-Jing Li; Ying Yang; Tian-You Wang; Zhi-Gang Li; Rui Zhang
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

Review 10.  The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.

Authors:  Alice Wang; Katelyn Singh; Wael Ibrahim; Brett King; William Damsky
Journal:  Yale J Biol Med       Date:  2020-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.